CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Multiple clinical trials have shown the efficacy of adoptively transferred allogeneic antigen-specific T cells for the treatment of viral infections and relapsed hematologic malignancies. In contrast, the therapeutic potential of autologous antigen-specific T cells has yet to be established since it has been technically difficult to generate sufficient numbers of these T cells, ex vivo. A major obstacle to the success of this objective derives from our inability to simply and rapidly isolate and/or expand large numbers of highly efficient antigen presenting cells (APCs) for repetitive stimulations of antigen-specific T cells in vitro. We show that autologous CD40-activated B cells represent a readily available source of highly efficient APC that appear to have several important advantages over other APCs for ex vivo T cell expansion including: (a) methodological simplicity necessary to generate continuously large numbers of APCs from just 50 cm3 of peripheral blood without loss of APC function; (b) capacity to induce high peak T cell proliferation and interferon-gamma production without IL-10 production; (c) ease in cryopreservation; and (d) markedly reduced cost. We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Earlier studies have shown that massive amounts of B cells can be obtained from small quantities of peripheral blood through activation by CD40 ligand, and are therefore a cost-effective source of autologous APC [15].”
From Ex vivo induction of viral antigen-specific CD8+ T cell responses using mRNA-electroporated CD40-activated B cells (2005) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129 · cited 3×
“Confirming the work of others (7), we observed that addition of TNF-a or CD40L to these cultures did not result in further expansion or prolonged viability of DCs (data not shown).”
BackgroundMethodKolb, H., Schattenberg, A., Goldman, J., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., & Niederwieser, D. (1995) · Blood · doi:10.1182/blood.v86.5.2041.bloodjournal8652041 · Cited by 1,934
Proliferating dendritic cell progenitors in human blood.
Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., & Schuler, G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.83 · Cited by 1,840
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804 · cited 1×
“Therefore, DCs have been selected as the “APC of choice” to generate antigen-specific T cells for immunotherapy (5, 6, 24, 25).”
MethodWalter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
Caux, C., Dezutter-Dambuyant, C., Schmitt, D., & Banchereau, J. (1992) · Nature · doi:10.1038/360258a0 · Cited by 1,554
Origin, maturation and antigen presenting function of dendritic cells
Cella, M., Sallusto, F., & Lanzavecchia, A. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80153-7 · Cited by 1,320
The CD40 Antigen and Its Ligand
Banchereau, J., Bazan, F., Blanchard, D., Brière, F., Galizzi, J., van Kooten, C., Liu, Y. J., Rousset, F., & Saeland, S. (1994) · Annual Review of Immunology · doi:10.1146/annurev.immunol.12.1.881 · Cited by 1,263
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,201
Cited by
Vonderheide, R. H., Hahn, W. C., Schultze, J. L., & Nadler, L. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80066-7 · Cited by 570
Self-citationCD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
French, R. R., Chan, H. T. C., Tutt, A. L., & Glennie, M. J. (1999) · Nature Medicine · doi:10.1038/8426 · Cited by 426
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Schwitalle, Y., Kloor, M., Eiermann, S., Linnebacher, M., Kienle, P., Knaebel, H. P., Tariverdian, M., Benner, A., & von Knebel Doeberitz, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.015 · Cited by 387
Single-cell spatial landscapes of the lung tumour immune microenvironment
Sorin, M., Rezanejad, M., Karimi, E., Fiset, B., Desharnais, L., Perus, L. J. M., Milette, S., Yu, M. W., Maritan, S. M., Doré, S., et al. (2023) · Nature · doi:10.1038/s41586-022-05672-3 · Cited by 367
Role of B cells as antigen presenting cells
Rastogi, I., Jeon, D., Moseman, J. E., Muralidhar, A., Potluri, H. K., & McNeel, D. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954936 · Cited by 352
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages
Momen-Heravi, F., Bala, S., Bukong, T., & Szabo, G. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2014.03.014 · Cited by 306
The Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 293
Tertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C. J., ten Bosch, G. J. A., Kester, M. G. D., Sijts, A., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.73 · Cited by 263
Principles of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Zand, M. S., Vo, T., Huggins, J., Felgar, R., Liesveld, J., Pellegrin, T., Bozorgzadeh, A., Sanz, I., & Briggs, B. J. (2005) · Transplantation · doi:10.1097/01.tp.0000164159.20075.16 · Cited by 237
“Unfractionated CD19 B cells were used to make CD40L- and IL-4 –activated B-cell blasts as previously described (10, 11).”
MethodPhase I Study of Recombinant Human CD40 Ligand in Cancer Patients
Vonderheide, R. H., Dutcher, J. P., Anderson, J. E., Eckhardt, S. G., Stephans, K. F., Razvillas, B., Garl, S., Butine, M. D., Perry, V. P., Armitage, R. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3280 · Cited by 223
“in immunoglobulin class switching and growth stimulation.(8-10) CD40 has been demonstrated on all normal B-”
BackgroundSelf-citationHoward, L. M., Miga, A. J., Vanderlugt, C. L., Canto, M. C. D., Laman, J. D., Noelle, R. J., & Miller, S. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5388 · Cited by 217
“CD154 (CD40L), the ligand for CD40, is transiently expressed primarily by activated CD4 T cells, although recently it has been identified on a subpopulation of activated B cells (23, 24).”
BackgroundProspect of Targeting the CD40 Pathway for Cancer Therapy
Vonderheide, R. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1893 · Cited by 186
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells
Latouche, J.-B., & Sadelain, M. (2000) · Nature Biotechnology · doi:10.1038/74455 · Cited by 175
“Transduced mouse fibroblasts provide an alternative cellular system that is very effective in activating B lymphoma cell”
BackgroundVan den Bosch, G. A., Ponsaerts, P., Nijs, G., Lenjou, M., Vanham, G., Van Bockstaele, D. R., Berneman, Z. N., & Van Tendeloo, V. F. I. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02733.x · Cited by 36
Metadata
- Authors
- Schultze, J. L., Michalak, S., Seamon, M. J., Dranoff, G., Jung, K., Daley, J., Delgado, J. C., Gribben, J. G., & Nadler, L. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-12-01
- Volume
- 100
- Issue
- 11
- Pages
- 2757-2765
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2028475115
- Cited by
- 355
- References
- 43
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.